RaySearch Laboratories, TomoTherapy terminate software licensing and development agreement

In 2007, RaySearch Laboratories AB (STO:RAYB) and TomoTherapy Incorporated (now Accuray) entered into a software licensing and development agreement. Under the agreement, RaySearch developed a product named SharePlan, which was launched by TomoTherapy in 2009.

SharePlan is an advanced treatment planning solution that enables transfer of treatment plans between TomoTherapy systems and conventional linear accelerators. The product uses highly sophisticated algorithms to automatically generate a selection of deliverable high-quality IMRT plans based on an existing TomoTherapy treatment plan. This time-saving concept is an important tool for optimizing patient benefit and throughput at clinics that have a mixed environment with both TomoTherapy systems and conventional linear accelerators.

Now RaySearch and Accuray have agreed to cancel the agreement and end the partnership. Although the partnership will be ending, Accuray and RaySearch are committed to ensuring that customer needs are supported and maintained. As a result, SharePlan functionality will continue to be available for new and existing customers as an integrated module in RaySearch's RayStation® treatment planning system that is sold and marketed by RaySearch. Existing SharePlan customers will be offered a free upgrade to RayStation®.

"Since the original agreement was signed, a lot has changed for both companies so this solution makes good sense for both parties. RayStation® was not available four years ago so back then a stand-alone application was the best solution. Now however, we can offer the same functionality in RayStation® which is evolving very rapidly and also gives the TomoTherapy System users the option to select other features and advanced treatment planning tools. This is attractive for the customers and Accuray alike as it expands the product offering for these customers", says Johan Löf, CEO of RaySearch.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Accelerate Your Research: Dispen3D Harnesses the Power of 3D Models